What is Biotium?
Biotium operates as a critical infrastructure provider for the life sciences sector, specializing in the development of high-performance fluorescent dyes, antibodies, and protein labeling kits. With a legacy spanning over two decades, the firm has established itself as a trusted partner for academic institutions and high-throughput research laboratories. Their product ecosystem is engineered to facilitate complex inquiries in fields such as oncology, neuroscience, and microbiology. By maintaining a rigorous focus on technical precision and reagent reliability, Biotium enables researchers to achieve reproducible results, thereby accelerating the pace of discovery in both fundamental and applied biological sciences.
How much funding has Biotium raised?
Biotium has raised a total of $919K across 2 funding rounds:
Debt
$350K
Debt
$569K
Debt (2020): $350K with participation from PPP
Debt (2021): $569K led by PPP
Key Investors in Biotium
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for Biotium?
With the recent influx of capital, Biotium is well-positioned to scale its enterprise-level operations and expand its global distribution network. The strategic allocation of these funds will likely prioritize the acceleration of R&D initiatives, specifically targeting the next generation of imaging technologies and high-sensitivity detection reagents. As the company transitions into this next phase of growth, the focus will remain on deepening its market penetration within the biotechnology sector while maintaining the high standards of technical support that have defined its brand. Future milestones will likely involve the integration of advanced manufacturing processes to meet the increasing demand for specialized cellular research tools, further cementing Biotium's role as a cornerstone of modern laboratory research.
See full Biotium company page
